OPTML / THE CLEARER PICTURE
What changed. And why.
A visible record of editorial and product changes. Dates below describe work performed, not a promise of daily monitoring.
2026-11-02 / CLARITY UPDATE
Understand the evidence before the claim.
- Added a separate evidence-context label to all 150 cards and guides. Labels describe source type, not an automatic quality score.
- Added question-led explanations with the cited finding and its limitation together.
- Expanded comparisons with population, design, measured outcome, regulatory context and risks. No ranking is inferred from different trials.
- Added guide-section navigation and this editorial-method page.
These changes reorganize the existing cited findings. They do not claim new medical review or refresh older source-check dates.
2026-11-02 / CONTENT COMPLETION
150 unique entries, with explicit boundaries.
The supplied spreadsheet contained 152 rows and 150 unique names; Tesamorelin and Trofinetide were duplicated. The library includes a written explanation for each unique entry, including product-label, identity-boundary, registry-only and evidence-gap guides.
Selected trial findings include negative endpoints and subgroup limitations. Bibliographic records are separate from appraised findings; unselected supplied links are excluded from public claim bibliographies.
Scope still matters.
This is not a worldwide inventory of every peptide, a systematic review of every claim, or a clinician-approved treatment directory. Read each guideās source-check date and limitations.
How we check sources